Easily accessible biomarkers are needed to diagnose cardiovascular disease precisely-particularly, to distinguish between disease subtypes that are encountered in clinical practice. Per the hypothesis that plasma miRNA is valuable for this purpose, we performed complete transcriptional profiling of an miRNA discovery-set in 14 samples: three patients with ST-elevanted acute myocardial infarction (STEMI) at baseline and after three months of follow-up, four with stable ischemic heart disease (stable-IHD), and four healthy age-matched volunteers. Our aim was to determine whether we could distinguish patients with unstable plaques from stable patients following a STEMI event. After analyzing miRNA profiles, we conducted a validation study comparing three-month STEMI (n = 40) with stable-IHD (n = 35), which confirmed that mir-486-3P differentiates patients with 3-month STEMI from those with stable IHD (P=0.019).
Wei, T., Folkersen, L., Ehrenborg, E., & Gabrielsen, A. (2016). MicroRNA 486-3P as a stability marker in acute coronary syndrome. Bioscience Reports, 36(3), e00351–e00351. https://doi.org/10.1042/bsr20160023